AIFinancial Timesabout 2 hours ago
Insilico Gets FDA Fast Track for ISM6331
1 min read
Insilico Medicine received FDA Fast Track designation for ISM6331, an AI-driven pan-TEAD inhibitor, for treating advanced mesothelioma. The designation aims to expedite development and regulatory review of the drug candidate.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
